A novel direct activator of AMPK inhibits prostate cancer growth by blocking lipogenesis

DSpace/Manakin Repository

A novel direct activator of AMPK inhibits prostate cancer growth by blocking lipogenesis

Citable link to this page

 

 
Title: A novel direct activator of AMPK inhibits prostate cancer growth by blocking lipogenesis
Author: Zadra, Giorgia; Photopoulos, Cornelia; Tyekucheva, Svitlana; Heidari, Pedram; Weng, Qing Ping; Fedele, Giuseppe; Liu, Hong; Scaglia, Natalia; Priolo, Carmen; Sicinska, Ewa; Mahmood, Umar; Signoretti, Sabina; Birnberg, Neal; Loda, Massimo

Note: Order does not necessarily reflect citation order of authors.

Citation: Zadra, G., C. Photopoulos, S. Tyekucheva, P. Heidari, Q. P. Weng, G. Fedele, H. Liu, et al. 2014. “A novel direct activator of AMPK inhibits prostate cancer growth by blocking lipogenesis.” EMBO Molecular Medicine 6 (4): 519-538. doi:10.1002/emmm.201302734. http://dx.doi.org/10.1002/emmm.201302734.
Full Text & Related Files:
Abstract: 5′AMP-activated kinase (AMPK) constitutes a hub for cellular metabolic and growth control, thus representing an ideal therapeutic target for prostate cancers (PCas) characterized by increased lipogenesis and activation of mTORC1 pathway. However, whether AMPK activation itself is sufficient to block cancer cell growth remains to be determined. A small molecule screening was performed and identified MT 63–78, a specific and potent direct AMPK activator. Here, we show that direct activation of AMPK inhibits PCa cell growth in androgen sensitive and castration resistant PCa (CRPC) models, induces mitotic arrest, and apoptosis. In vivo, AMPK activation is sufficient to reduce PCa growth, whereas the allelic loss of its catalytic subunits fosters PCa development. Importantly, despite mTORC1 blockade, the suppression of de novo lipogenesis is the underpinning mechanism responsible for AMPK-mediated PCa growth inhibition, suggesting AMPK as a therapeutic target especially for lipogenesis-driven PCas. Finally, we demonstrate that MT 63–78 enhances the growth inhibitory effect of AR signaling inhibitors MDV3100 and abiraterone. This study thus provides a rationale for their combined use in CRPC treatment.
Published Version: doi:10.1002/emmm.201302734
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3992078/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:12152848
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters